Head-to-head · WeighScore
Harbor vs TRYM Health
By GLP-1 ScorecardUpdated
Score comparison
Harbor has the higher recorded score — 72/100 to 70.6/100, but only just.
Harbor grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Harbor is a physician-led telehealth platform offering compounded semaglutide (from $99/mo) and compounded tirzepatide (from $149/mo) — among the lowest headline prices in the market. TRYM Health is close behind and may still be the better fit — see the factor split below.
Before you choose
Before comparing the headline prices, the Harbor review and the TRYM Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Harbor vs Vitara RX and Live Vital vs TRYM Health compare each of them with another graded program, and the list of alternatives to Harbor ranks the programs closest to Harbor on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the GoodLife Health review covers one graded close to these two, at 69.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Harbor | TRYM Health |
|---|---|---|
| WeighScore | 72/100 | 70.6/100 |
| Grade | C | C |
| Site position | #94 | #114 |
| Semaglutide | $99/mo (starting dose, compounded) | $96/mo (all doses, compounded) |
| Tirzepatide | $149/mo (starting dose, compounded) | $126/mo (all doses, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Compounded semaglutide from $99/mo and tirzepatide from $149/mo — among the lowest headline prices in the market
- LegitScript certified with 4.7-star rating, 94.6% success rate, and 10,000+ verified members
- 24/7 physician access with ongoing consultations, dosage adjustments, and free discreet shipping
- 12-Month Money Back Guarantee if you don't reach your weight-loss goal
- HSA/FSA eligible; no hidden fees, no insurance billed
What to consider
- Compounded medications are not FDA-approved; compounding pharmacy names not publicly disclosed
- Dietitian support offered only post-program (maintenance phase), not during active treatment
- State-specific consultation types vary; nationwide availability unconfirmed for all states
- No labs disclosed; patient portal is a third-party platform (mdintegrations), not native
- Newer brand; success rate and member counts are on-site claims, not third-party verified
FDAWarning letter issued to TRYM Health, Inc. dba TRYM Health in September 2025. See the FDA warning-letter database.
Strengths
- Affordable compounded GLP-1 — semaglutide ~$96/mo ($3.20/day) and tirzepatide ~$126/mo ($4.20/day)
- Available in all 50 states with free shipping and FSA/HSA eligibility
- Multi-dose vials cover all doses up to the maximum; additive-free, with a full starter kit
- Temperature-controlled insulated shipping and flexible cancellation
What to consider
- Compounding pharmacy partner not named
- LegitScript certification was not documented on the public pages reviewed
- Lowest per-day pricing likely requires a longer prepaid plan commitment
- Drugs labeled generically as 'GLP-1' / 'GLP-1 + GIP' on the services page rather than named
- FDA issued TRYM Health, Inc. dba TRYM Health a warning letter in September 2025; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.